Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
AIMS The aim of this study was to determine the outcome benefits in those originally assigned atorvastatin in the Anglo-Sc and inavian Cardiac Outcomes Trial-8 years after closure of the lipid-lowering arm ( LLA ) of the trial ( ASCOT-LLA ) among the U.K. population . METHODS AND RESULTS ASCOT-LLA was a factorially design ed double-blind placebo-controlled trial of atorvastatin in 10 305 hypertensive patients enrolled into the ASCOT-Blood Pressure Lowering Arm ( BPLA ) of the trial and with total cholesterol concentrations , at baseline , of < 6.5 mmol/L. ASCOT-LLA was stopped prematurely after a median 3.3-year follow-up because of a 36 % relative risk reduction ( RRR ) in non-fatal myocardial infa rct ion and fatal coronary heart disease ( CHD ) ( the primary outcome ) in favour of atorvastatin and a non-significant reduction in CV deaths ( 16 % ) and all-cause mortality ( 13 % ) . After a further 2.2 years at the end of ASCOT-BPLA , despite extensive crossovers from and to statin usage , the RRR in all endpoints remained essentially unchanged . A median 11 years after initial r and omization and ∼8 years after closure of LLA , all-cause mortality ( n=520 and 460 in placebo and atorvastatin , respectively ) remained significantly lower in those originally assigned atorvastatin ( HR 0.86 , CI 0.76 - 0.98 , P=0.02 ) . CV deaths were fewer , but not significant ( HR 0.89 , CI 0.72 - 1.11 , P=0.32 ) and non-CV deaths were significantly lower ( HR 0.85 , CI 0.73 - 0.99 , P=0.03 ) in those formerly assigned atorvastatin attributed to a reduction in deaths due to infection and respiratory illness . CONCLUSION Legacy effects of those originally assigned atorvastatin may contribute to long-term benefits on all-cause mortality . An explanation for long-term benefits on non-CV deaths has not been established
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .